“The new GLP-1 pill works just as well as the injections.”
What the evidence shows
There is now a real oral option. In April 2026 the FDA approved orforglipron (brand name Foundayo), a once-daily small-molecule GLP-1 pill that, unlike earlier oral peptides, can be taken any time of day without food or water restrictions. In its 72-week phase-3 program (ATTAIN-1), the highest dose produced about 12.4% average weight loss versus roughly 0.9% on placebo. The oral form of semaglutide (a Wegovy pill) lands in a similar range in its trials. That's a lot of weight — but the strongest injectables go further. In the head-to-head SURMOUNT-5 trial, injectable tirzepatide produced about 20% weight loss versus about 14% for injectable semaglutide, and the investigational triple-agonist retatrutide reached roughly a quarter of body weight in earlier trials. So today's pills roughly match injectable semaglutide but generally trail tirzepatide and the investigational agents.
What we still don’t know
There's no head-to-head randomized trial of orforglipron against tirzepatide, so the comparison is across different trials with different participants — a rough guide, not a precise ranking. Individual response varies a lot; some people do better on a given pill than the trial averages suggest. Long-term durability of the newer pills, and whether higher-dose or next-generation oral formulations could close the gap, are still open questions.
Why the claim misleads
"Just as well" flattens a real and clinically meaningful gap: a pill delivering ~12% and a shot delivering ~20% are not the same result, even though both are effective. The opposite spin — dismissing pills as inferior — also misses the point, because for people who won't or can't inject, or who struggle with cost and cold storage, an oral option that works is a major access win. The accurate framing is that pills widened the door, but the top injectables still produce more weight loss on average — and which is right for a given person is a clinician conversation, not a one-size headline.
Graded by The Peptide Era · evidence, not hype